- Notification that Quarterly Report will be submitted late (NT 10-Q)
November 16 2010 - 6:12AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
|
|
SEC
FILE NUMBER
|
|
|
000-51312
|
|
FORM
12b-25
|
CUSIP
NUMBER
|
|
|
823214101
|
NOTIFICATION
OF LATE FILING
(Check
One):
|
¨
|
Form
10-K
|
¨
|
Form
20-F
|
¨
|
Form
11-K
|
x
|
Form
10-Q
|
¨
|
Form
10D
|
¨
|
Form
N-SAR
|
|
¨
|
Form
N-CSR
|
|
|
|
|
|
|
|
|
|
|
For
Period Ended:
September
30,
2010
¨
Transition Report on
Form 10-K
¨
Transition Report on
Form 20-F
¨
Transition Report on
Form 11-K
¨
Transition Report on
Form 10-Q
¨
Transition Report on
Form N-SAR
For the
Transition Period Ended:
Nothing in this form
shall be construed to imply that the Commission has verified any
information contained herein
.
|
If
the notification relates to a portion of the filing checked above,
identify the Item(s) to which the notification relates:
|
|
PART
I — REGISTRANT INFORMATION
Shengtai Pharmaceuticals,
Inc.
|
Full
name of Registrant
|
West Coast Car Co.
|
Former
Name if Applicable
|
Changda Road East
|
Address
of Principal Executive Office
(Street and
number)
|
Development District, Changle County, Shandong,
The People’s Republic of China Post Code: 262400
|
City,
State and Zip Code
|
PART
II — RULE 12b-25(b) AND (c)
If the
subject report could not be filed without unreasonable effort or expense and the
registrant seeks relief pursuant to Rule 12b-25(b), the following should be
completed. (Check box if appropriate.)
|
(a)
|
The
reasons described in reasonable detail in Part III of this form could not
be eliminated without unreasonable effort or expense;
|
|
|
|
x
|
(b)
|
The
subject annual report, semi-annual report, transition report on Form 10-K,
Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof will be
filed on or before the Fifteenth calendar day following the prescribed due
date; or the subject quarterly report or transition report on Form 10-Q or
subject distribution report on Form 10-D, or portion thereof, will be
filed on or before the fifth calendar day following the prescribed due
date; and
|
|
|
|
|
(c)
|
The
accountant’s statement or other exhibit required by Rule 12b-25(c) has
been attached if
applicable.
|
PART
III — NARRATIVE
State
below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, N-SAR, N-CSR, or
the transition report or portion thereof, could not be filed within the
prescribed time period. (Attach extra sheets if needed.)
The
compilation, dissemination and review of the information required to be
presented in the Form 10-Q for the relevant period has imposed time constraints
that have rendered timely filing of the Form 10-Q impracticable without undue
hardship and expense to the registrant. The registrant undertakes the
responsibility to file such report no later than the fifth day after its
original prescribed due date.
PART
IV — OTHER INFORMATION
1.
|
Name and telephone number of
person to contact in regard to this
notification
|
Ye Hu
|
|
86
|
|
536-6295802
|
(Name)
|
|
(Area
Code)
|
|
(Telephone
Number)
|
2.
|
Have
all other periodic reports required under Section 13 or 15(d) of the
Securities Exchange Act of 1934 or Section 30 of the Investment Company
Act of 1940 during the preceding 12 months or for such shorter period that
the registrant was required to file such report(s) been
filed? If the answer is no, identify report(s).
x
Yes
¨
No
|
3.
|
Is
it anticipated that any significant change in results of operations from
the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion
thereof?
o
Yes
x
No
|
If
so: attach an explanation of the anticipated change, both narratively
and quantitatively, and, if appropriate, state the reasons why a reasonable
estimate of the results cannot be made.
|
Shengtai
Pharmaceuticals, Inc.
|
|
|
(Name
of Registrant as Specified in Charter)
|
|
has
caused this notification to be signed on its behalf by the undersigned thereunto
duly authorized.
Dated:
November 16, 2010
|
By:
|
/s/
Qingtai
Liu
|
|
Name:
Qingtai Liu
|
|
Title:
Chief Executive Officer
|
Shengtai Pharmaceutical (GM) (USOTC:SGTI)
Historical Stock Chart
From Sep 2024 to Oct 2024
Shengtai Pharmaceutical (GM) (USOTC:SGTI)
Historical Stock Chart
From Oct 2023 to Oct 2024